Cargando…

PB2292: DEVELOPMENT OF CARDIOTOXICITY NEGATIVELY IMPACTS IN OVERALL SURVIVAL IN PATIENTS WITH LYMPHOMA TREATED WITH FIRST-LINE ANTHRACYCLINES

Detalles Bibliográficos
Autores principales: Garcia, Alberto Lopez, Macia, Ester, Gomez-Talavera, Sandra, Castillo-Bazan, Eva, Morillo, Daniel, Ibañez, Borja, Cordoba, Raul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429679/
http://dx.doi.org/10.1097/01.HS9.0000975896.32740.f9
_version_ 1785090773305262080
author Garcia, Alberto Lopez
Macia, Ester
Gomez-Talavera, Sandra
Castillo-Bazan, Eva
Morillo, Daniel
Ibañez, Borja
Cordoba, Raul
author_facet Garcia, Alberto Lopez
Macia, Ester
Gomez-Talavera, Sandra
Castillo-Bazan, Eva
Morillo, Daniel
Ibañez, Borja
Cordoba, Raul
author_sort Garcia, Alberto Lopez
collection PubMed
description
format Online
Article
Text
id pubmed-10429679
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-104296792023-08-17 PB2292: DEVELOPMENT OF CARDIOTOXICITY NEGATIVELY IMPACTS IN OVERALL SURVIVAL IN PATIENTS WITH LYMPHOMA TREATED WITH FIRST-LINE ANTHRACYCLINES Garcia, Alberto Lopez Macia, Ester Gomez-Talavera, Sandra Castillo-Bazan, Eva Morillo, Daniel Ibañez, Borja Cordoba, Raul Hemasphere Publication Only Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10429679/ http://dx.doi.org/10.1097/01.HS9.0000975896.32740.f9 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
spellingShingle Publication Only
Garcia, Alberto Lopez
Macia, Ester
Gomez-Talavera, Sandra
Castillo-Bazan, Eva
Morillo, Daniel
Ibañez, Borja
Cordoba, Raul
PB2292: DEVELOPMENT OF CARDIOTOXICITY NEGATIVELY IMPACTS IN OVERALL SURVIVAL IN PATIENTS WITH LYMPHOMA TREATED WITH FIRST-LINE ANTHRACYCLINES
title PB2292: DEVELOPMENT OF CARDIOTOXICITY NEGATIVELY IMPACTS IN OVERALL SURVIVAL IN PATIENTS WITH LYMPHOMA TREATED WITH FIRST-LINE ANTHRACYCLINES
title_full PB2292: DEVELOPMENT OF CARDIOTOXICITY NEGATIVELY IMPACTS IN OVERALL SURVIVAL IN PATIENTS WITH LYMPHOMA TREATED WITH FIRST-LINE ANTHRACYCLINES
title_fullStr PB2292: DEVELOPMENT OF CARDIOTOXICITY NEGATIVELY IMPACTS IN OVERALL SURVIVAL IN PATIENTS WITH LYMPHOMA TREATED WITH FIRST-LINE ANTHRACYCLINES
title_full_unstemmed PB2292: DEVELOPMENT OF CARDIOTOXICITY NEGATIVELY IMPACTS IN OVERALL SURVIVAL IN PATIENTS WITH LYMPHOMA TREATED WITH FIRST-LINE ANTHRACYCLINES
title_short PB2292: DEVELOPMENT OF CARDIOTOXICITY NEGATIVELY IMPACTS IN OVERALL SURVIVAL IN PATIENTS WITH LYMPHOMA TREATED WITH FIRST-LINE ANTHRACYCLINES
title_sort pb2292: development of cardiotoxicity negatively impacts in overall survival in patients with lymphoma treated with first-line anthracyclines
topic Publication Only
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429679/
http://dx.doi.org/10.1097/01.HS9.0000975896.32740.f9
work_keys_str_mv AT garciaalbertolopez pb2292developmentofcardiotoxicitynegativelyimpactsinoverallsurvivalinpatientswithlymphomatreatedwithfirstlineanthracyclines
AT maciaester pb2292developmentofcardiotoxicitynegativelyimpactsinoverallsurvivalinpatientswithlymphomatreatedwithfirstlineanthracyclines
AT gomeztalaverasandra pb2292developmentofcardiotoxicitynegativelyimpactsinoverallsurvivalinpatientswithlymphomatreatedwithfirstlineanthracyclines
AT castillobazaneva pb2292developmentofcardiotoxicitynegativelyimpactsinoverallsurvivalinpatientswithlymphomatreatedwithfirstlineanthracyclines
AT morillodaniel pb2292developmentofcardiotoxicitynegativelyimpactsinoverallsurvivalinpatientswithlymphomatreatedwithfirstlineanthracyclines
AT ibanezborja pb2292developmentofcardiotoxicitynegativelyimpactsinoverallsurvivalinpatientswithlymphomatreatedwithfirstlineanthracyclines
AT cordobaraul pb2292developmentofcardiotoxicitynegativelyimpactsinoverallsurvivalinpatientswithlymphomatreatedwithfirstlineanthracyclines